ERBB2 and breast carcinoma: However, a significant number of patients with breast cancer, in particular those with basal-like breast cancer, which lacks expression of estrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2), still face a poor prognosis with a high risk of recurrence or drug resistance 3, 4.